TERIPET

Treatment tested

• Teriflunomide

  Dihydroorotate dehydrogenase inhibitor

Other measures (4)

Inclusion Criteria: * Signing the consent form * Having used teriflunomide treatment for at least 6 months * 40-55 years of age at the time of signing the research consent form * MS diagnosis in accordance with either the Poser or McDonald criteria * EDSS 2-6.5 * Clear lesion load in brain MRI (> 9 T2 lesion) Exclusion Criteria: * Patients suffering from another brain disease of in addition to multiple sclerosis * Steroid treatment 4 weeks prior to the scan * Significant pathology in the MRI scan other than MS-related lesions * Patients suffering from claustrophobia or panic disorder, or patients who have exhibited hypersensitivity of PET markers (practical obstacle to the scan) * Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study * Severe hepatic impairment * Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with teriflunomide and thereafter as long as its plasma levels are above 0.02 mg/l.

To evaluate the effect of teriflunomide treatment on microglial activation in late stage multiple sclerosis.